Combined salmeterol 50 μg and fluticasone propionate 250 in the diskus device for the treatment of asthma

American Journal of Respiratory and Critical Care Medicine

Volumn 161, Issue 2 I, 2000, Pages 527-534

  Shapiro, Gail ^a   Lumry, William ^b   Wolfe, James ^b   Given, John ^b   White, Martha V ^b   Woodring, Anita ^b   Baitinger, Leslie ^b   House, Karen ^b   Prillaman, Barbara ^b   Shah, Tushar ^b  

^a Asthma Inc   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; FLUNISOLIDE; FLUTICASONE PROPIONATE; SALBUTAMOL; SALMETEROL; TRIAMCINOLONE ACETONIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; STEROID THERAPY;

EID: 0034099011     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.161.2.9905091     Document Type: Article

References (35)

1. Highlights of the expert panel report 2: Guidelines for the diagnosis and management of asthma. 1997. National Institutes of Health (National Heart, Lung, and Blood Institute), Bethesda, MD. Publication No. 97-4051A. 1-50.
2. Vignola, A. M., P. Chanez, A. M. Campbell, F. Souques, B. Lebel, I. Enander, and J. Bousquet. 1998. Airway inflammation in mild intermittent and in persistent asthma. Am. J. Respir. Crit. Care Med 157:403-409.
3. Djukanovic, R., J. W. Wilson, K. M. Britten, S. J. Wilson, A. F. Walls, W. R. Roche, P. H. Howarth, and S. T. Holgate. 1992. Effect of an inhaled corticosteroid on airway inflammation and symptoms of asthma. Am. Rev. Respir. Dis. 145:669-674.
4. Jeffery, P. K., R. W. Godfrey, E. Adelroth, F. Nelson, A. Rogers, and S. A. Johannson. 1992. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma: a quantitative light and electron microscopic study. Am. Rev. Respir. Dis. 145:890-899.
5. 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized double-blind, parallel-group controlled trial. J. Allergy Clin. Immunol. 90:32-42.
6. Barnes, P. J., S. Pedersen, and W. W. Busse. 1998. Efficacy and safety of inhaled corticosteroids. Am. J. Respir. Crit. Care Med. 157(Suppl.):S1-S53.
7. Cochrane, G. M. Compliance in asthma. 1998. Eur. Respir. Rev. 8:239-242.
8. Greening, A. P., P. W. Ind, M. Northfield, and G. Shaw. 1994. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 344:219-224.
9. Woolcock, A., B. Lundback, N. Ringdal, and L. A. Jacques. 1996. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am. J. Respir. Crit. Care Med. 153:1481-1488.
10. Condemi, J. J., S. Goldstein, C. Kalberg, S. Yancey, A. Emmett, K. Rickard, and the Salmeterol Study Group. 1999. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Ann. Allergy Asthma Immunol. 82:383-389.
11. Chung, K. F. 1998. The complementary role of glucocorticosteroids and long-acting β-adrenergic agonists. Allergy 53:7-13.
12. Oddera, S., M. Silvestri, R. Testi, and G. A. Rossi. 1998. Salmeterol enhances the inhibitory activity of dexamethasone on allergen-induced blood mononuclear cell activation. Respiration 65:199-204.
13. 2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J. Biol. Chem. 274: 1005-1010.
14. Pearlman, D. S., P. Chervinsky, C. LaForce, J. M. Seltzer, D. L. Southern, J. P. Kemp, R. J. Dockhorn, J. Grossman, R. F. Liddle, S. W. Yancey, D. M. Cocchetto, W. J. Alexander, and A. van As. 1992. A comparison of salmeterol with albuterol in the treatment of mild to moderate asthma. N. Engl. J. Mat. 327:1420-1425.
15. D'Alonzo, G. E., R. A. Nathan, S. Henochowicz, R. J. Morris, P. Ratner, and S. I. Rennard. 1994. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. J.A.M.A. 271:1412-1416.
16. Britton, M. G., J. S. Earnshaw, and J. B. D. Palmer. 1992. A twelve-month comparison of salmeterol with salbutamol in asthmatic patients. Eur. Respir. J. 5:1062-1067.
17. Barnes, N., C. Hallett, and T. Harris. 1998. Clinical experience with fluticasone propionate in asthma: a meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less. Respir. Med. 92:95-104.
18. Li, J. T. C., M. F. Goldstein, G. N. Gross, M. J. Noonan, S. Weisberg, L. Edwards, K. D. Reed, and P. R. Rogenes. 1999. Effects of fluticasone propionate, triamcinolone acetonide, prednisone, and placebo on the hypothalamic-pituitary-adrenal axis. J. Allergy Clin. Immunol. 103:622-629.
19. Srebro, S. H., H. H. Weber, P. R. Rogenes, L. Edwards, and the FP Clinical Study Group. 1998. Comparison of fluticasone propionate with flunisolide in patients with mild to moderate asthma (abstract). J. Allergy Clin. Immunol. 101(1, Pt. 2):S6.
20. Sorkness C. A., C. LaForce, W. Storms, W. R. Lincourt, L. Edwards, and P. R. Rogenes. 1999. Effects of the inhaled corticosteroids fluticasone propionate, triamcinolone acetonide, and flunisolide and oral prednisone on the hypothalamic-pituitary-adrenal axis in adult patients with asthma. Clin. Ther. 21:353-367.
21. Kemp, J., J. Wolfe, J. Grady, C. LaForce, E. Stahl, T. Arledge, and R. Liddle. 1998. Salmeterol powder compared with albuterol aerosol as maintenance therapy for asthma in adolescent and adult patients. Clin. Ther. 20:270-282.
22. Weinstein, S, F., D. S. Pearlman, E. A. Bronsky, A. Byrne, T. Arledge, R. Liddle, and E. Stahl. 1998. Efficacy of salmeterol powder in children with chronic persistent asthma. Ann. Allergy Asthma Immunol. 81:51-58.
23. Galant S. P., J. van Bavel, A. Finn, G. Gross, W. Pleskow, A. Brown, A. G. Hamedani, and S. M. Harding. 1999. Diskus and Diskhaler: efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma. Ann. Allergy Asthma Immunol. 82:273-280.
24. Peden, D. B., W. E. Berger, M. J. Noonan, M. R. Thomas, V. L. Hendricks, A. G. Hamedani, P. Mahajan, and K. W. House. 1998. Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pcdiatric population with persistent asthma. J. Allergy Clin. Immunol. 102:32-38.
25. Fuller, R. 1995. A new multi-dose powder device - efficacy and comparison with Turbuhaler. J. Aerosol Med. Deposition Clear. Eff. Lung 8(Suppl. 2):S11-S17.
26. Williams, J., and K. A. Richards. 1997. Ease of handling and clinical efficacy of fluticasone propionate accuhaler Diskus inhaler compared with the Turbohaler inhaler in pediatric patients. Br. J. Clin. Pract. 51: 147-153.
27. Sehlaeppi, M., K. Edwards, and R. W. Fuller. 1996. Patient perception of the Diskus inhaler: a comparison with the Turbuhaler inhaler. Br. J. Clin. Pract. 50:14-19.
28. American Thoracic Society. 1995. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am. J. Respir. Crit. Care Med. 152:77-120.
29. Quanjer, P. H. 1983. Report of the working party of the European community for coal and steel: standardisation of lung function tests. Pergamon Press, Oxford, UK. 1-94.
30. Polgar, G., and V. Promadhat. 1971. Pulmonary Function Testing in Children: Techniques and Standards. WB Saunders, Philadelphia. 1-269.
31. Crapo, R., A. Morris, and R. Gardner. 1989. Reference values for lung function tests. Respir. Care 34:626-637.
32. Szefler, S. J., H. A. Boushey, D. S. Pearlman, A. Togias, R. Liddle, A. Furlong, T. Shah, K. Knobil. 1999. Time to onset of effect of fluticasone propionate in patients with asthma. J. Allergy Clin. Immunol. 103: 780-788.
33. Pauwels, R. A., C.-G. Lofdahl, D. S. Postma, A. E. Tattersfield, P. O'Byrne, P. J. Barnes, and A. Ullman. 1997. Effect of inhaled formotcrol and budesonide on exacerbations of asthma. N. Engl. J. Med. 337: 1405-1411.
34. Edwards, T., G. Gross, D. Mitchell, P. Chervinsky, A. Woodring, L. Baitinger, B. Prillaman, K. House, and T. Shah. 1998. The salmeterol xinafoate/fluticasone propionate dry powder combination product via Diskus inhaler improves asthma control compared to salmeterol xinafoate or fluticasonc propionate dry powder alone (abstract). Am. J. Respir. Crit. Care Med. 157:A414.
35. Pieters, W. R., K.-O. Steinmetz M. Aubier, L. Johnson, E. Gomez, and M. Bogolubov. 1998. Effectiveness of a new salmeterol/fluticasone propionate (50/500 μg) combination inhaler in patients with reversible airways obstruction (abstract). Eur. Respir. J. 12(Suppl. 28):35S.